188 related articles for article (PubMed ID: 35094171)
1. Neurofilament light chain as a disease severity biomarker in ATTRv: data from a single-centre experience.
Luigetti M; Di Paolantonio A; Guglielmino V; Romano A; Rossi S; Sabino A; Servidei S; Sabatelli M; Primiano G
Neurol Sci; 2022 Apr; 43(4):2845-2848. PubMed ID: 35094171
[TBL] [Abstract][Full Text] [Related]
2. Serum neurofilament light chain: a promising early diagnostic biomarker for hereditary transthyretin amyloidosis?
Romano A; Primiano G; Antonini G; Ceccanti M; Fenu S; Forcina F; Gentile L; Inghilleri M; Leonardi L; Manganelli F; Obici L; Sabino A; Sciarrone MA; Tozza S; Vitali F; Luigetti M
Eur J Neurol; 2024 Jan; 31(1):e16070. PubMed ID: 37724995
[TBL] [Abstract][Full Text] [Related]
3. Pupillometric findings in ATTRv patients and carriers: results from a single-centre experience.
Romano A; Guglielmino V; Di Paolantonio A; Bisogni G; Sabatelli M; Della Marca G; Minnella AM; Maceroni M; Bellavia S; Scala I; Sabatelli E; Rollo E; Luigetti M
Amyloid; 2022 Dec; 29(4):270-275. PubMed ID: 36066019
[TBL] [Abstract][Full Text] [Related]
4. Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis.
Ticau S; Sridharan GV; Tsour S; Cantley WL; Chan A; Gilbert JA; Erbe D; Aldinc E; Reilly MM; Adams D; Polydefkis M; Fitzgerald K; Vaishnaw A; Nioi P
Neurology; 2021 Jan; 96(3):e412-e422. PubMed ID: 33087494
[TBL] [Abstract][Full Text] [Related]
5. Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice.
Carroll AS; Razvi Y; O'Donnell L; Veleva E; Heslegrave A; Zetterberg H; Vucic S; Kiernan MC; Rossor AM; Gillmore JD; Reilly MM
Amyloid; 2024 Jun; 31(2):95-104. PubMed ID: 38348665
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers of axonal damage to favor early diagnosis in variant transthyretin amyloidosis (A-ATTRv).
González-Moreno J; Gragera-Martínez Á; Rodríguez A; Borrachero-Garro C; García-Garrido S; Barceló C; Manovel-Sánchez A; Ribot-Sansó MA; Ibargüen-González L; Gomila R; Muñoz-Beamud F; Losada-López I; Cisneros-Barroso E
Sci Rep; 2024 Jan; 14(1):581. PubMed ID: 38182630
[TBL] [Abstract][Full Text] [Related]
7. Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study.
Ticau S; Aldinc E; Polydefkis M; Adams D; Coelho T; Ueda M; Hale C; Vest J; Nioi P;
Amyloid; 2024 Mar; 31(1):1-11. PubMed ID: 37469249
[TBL] [Abstract][Full Text] [Related]
8. Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis.
Louwsma J; Brunger AF; Bijzet J; Kroesen BJ; Roeloffzen WWH; Bischof A; Kuhle J; Drost G; Lange F; Kuks JBM; Gans ROB; Hazenberg BPC; Nienhuis HLA
Amyloid; 2021 Mar; 28(1):50-55. PubMed ID: 32883119
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis.
Berends M; Brunger AF; Bijzet J; Kroesen BJ; Drost G; Lange F; Teunissen CE; In 't Veld S; Vrancken AF; Gans ROB; Hazenberg BPC; van der Zwaag PA; Nienhuis HLA
Amyloid; 2024 Jun; 31(2):132-141. PubMed ID: 38477065
[TBL] [Abstract][Full Text] [Related]
10. Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy.
Maia LF; Maceski A; Conceição I; Obici L; Magalhães R; Cortese A; Leppert D; Merlini G; Kuhle J; Saraiva MJ
Amyloid; 2020 Jun; 27(2):97-102. PubMed ID: 31906707
[No Abstract] [Full Text] [Related]
11. Serum neurofilament light chain as a reliable biomarker of hereditary transthyretin-related amyloidosis-A Swiss reference center experience.
Loser V; Benkert P; Vicino A; Lim Dubois Ferriere P; Kuntzer T; Pasquier J; Maceski A; Kuhle J; Theaudin M
J Peripher Nerv Syst; 2023 Mar; 28(1):86-97. PubMed ID: 36471582
[TBL] [Abstract][Full Text] [Related]
12. Muscle MRI as a Useful Biomarker in Hereditary Transthyretin Amyloidosis: A Pilot Study.
Primiano G; Verdolotti T; D'Apolito G; Di Paolantonio A; Guglielmino V; Romano A; Lucioli G; Luigetti M; Servidei S
Genes (Basel); 2021 Nov; 12(11):. PubMed ID: 34828392
[TBL] [Abstract][Full Text] [Related]
13. Muscle quantitative MRI as a novel biomarker in hereditary transthyretin amyloidosis with polyneuropathy: a cross-sectional study.
Vegezzi E; Cortese A; Bergsland N; Mussinelli R; Paoletti M; Solazzo F; Currò R; Ascagni L; Callegari I; Quartesan I; Lozza A; Deligianni X; Santini F; Marchioni E; Cosentino G; Alfonsi E; Tassorelli C; Bastianello S; Merlini G; Palladini G; Obici L; Pichiecchio A
J Neurol; 2023 Jan; 270(1):328-339. PubMed ID: 36064814
[TBL] [Abstract][Full Text] [Related]
14. Neurological affection and serum neurofilament light chain in wild type transthyretin amyloidosis.
Pernice HF; Knorz AL; Wetzel PJ; Herrmann C; Muratovic H; Rieber F; Asaad E; Fiß G; Barzen G; Blüthner E; Knebel F; Spethmann S; Messroghli D; Heidecker B; Brand A; Wetz C; Tschöpe C; Hahn K
Sci Rep; 2024 May; 14(1):10111. PubMed ID: 38698025
[TBL] [Abstract][Full Text] [Related]
15. Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis.
Leonardi L; Adam C; Beaudonnet G; Beauvais D; Cauquil C; Not A; Morassi O; Benmalek A; Trassard O; Echaniz-Laguna A; Adams D; Labeyrie C
Eur J Neurol; 2022 May; 29(5):1477-1487. PubMed ID: 35100482
[TBL] [Abstract][Full Text] [Related]
16. Neurofilament Light Chains in Systemic Amyloidosis: A Systematic Review.
Berends M; Nienhuis HLA; Adams D; Karam C; Luigetti M; Polydefkis M; Reilly MM; Sekijima Y; Hazenberg BPC
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612579
[TBL] [Abstract][Full Text] [Related]
17. Plasma growth differentiation factor 15: a novel tool to detect early changes of hereditary transthyretin amyloidosis.
Okada M; Misumi Y; Masuda T; Takashio S; Tasaki M; Matsushita H; Ueda A; Inoue Y; Nomura T; Nakajima M; Yamashita T; Shinriki S; Matsui H; Tsujita K; Ando Y; Ueda M
ESC Heart Fail; 2021 Apr; 8(2):1178-1185. PubMed ID: 33381924
[TBL] [Abstract][Full Text] [Related]
18. Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy.
Maalmi H; Strom A; Petrera A; Hauck SM; Strassburger K; Kuss O; Zaharia OP; Bönhof GJ; Rathmann W; Trenkamp S; Burkart V; Szendroedi J; Ziegler D; Roden M; Herder C;
Diabetologia; 2023 Mar; 66(3):579-589. PubMed ID: 36472640
[TBL] [Abstract][Full Text] [Related]
19. Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis.
Lin X; Yarlas A; Vera-Llonch M; Baranwal N; Biber J; Brown D; Vogt B; Karam C
BMC Neurol; 2021 Feb; 21(1):70. PubMed ID: 33579211
[TBL] [Abstract][Full Text] [Related]
20. Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3.
Li QF; Dong Y; Yang L; Xie JJ; Ma Y; Du YC; Cheng HL; Ni W; Wu ZY
Mol Neurodegener; 2019 Nov; 14(1):39. PubMed ID: 31684998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
